Theracap131

Theracap131 contains Sodium Iodide (131i) for oral use, a radiopharmaceutical used in nuclear medicine. It supports thyroid imaging and therapy under medical supervision. Suitable for patients requiring radioactive iodine treatment. Short-term use only.

Sodium Iodide (131i) is primarily used in nuclear medicine for diagnostic imaging and therapeutic treatment of thyroid disorders. It helps assess thyroid function and manage conditions like hyperthyroidism or thyroid cancer. The radioactive iodine targets thyroid tissue for evaluation or reduction. Commonly prescribed when non-radioactive alternatives are insufficient.

After oral administration, Sodium Iodide (131i) is absorbed by the thyroid gland, where it emits radiation to aid imaging or treatment. Patients may notice mild effects like a metallic taste or temporary thyroid sensitivity. Radioactive iodine works gradually, with effects becoming apparent over days or weeks. Hydration and dietary precautions are recommended during use.

Sodium Iodide (131i) should only be handled and administered by trained healthcare professionals in controlled settings. Pregnant or breastfeeding individuals must avoid exposure due to radiation risks. Patients should follow specific pre- and post-treatment guidelines, including avoiding close contact with others for a period. Disposal of bodily waste must comply with local radiation safety regulations.

Certain medications, such as thyroid hormones or iodine-containing supplements, may interfere with the uptake of Sodium Iodide (131i). Patients should inform their healthcare provider about all current medications, including over-the-counter drugs. Alcohol and specific foods may also affect thyroid function and should be discussed with a medical professional. Radiopharmaceuticals like this require careful timing with other treatments.